Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Silo Pharma Inc (NQ: SILO )

1.180 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions
Via Investor Brand Network
What You Should Know About Colorado’s Psychedelics Ballot Measure
Via Investor Brand Network
Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway
Via Investor Brand Network
Silo Pharma Extends Alzheimer's Therapeutics Research Pact
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Data Supporting SPC-14’s Therapeutic Potential for Alzheimer’s
Via Investor Brand Network
Exposures Product Safety
What Is Going on With Silo Pharma (SILO) Stock Today?
Silo Pharma (SILO) stock is falling on Thursday despite the company releasing positive data from a pre-clinical Alzheimer's study. 
Via InvestorPlace
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which... 
Via FinancialNewsMedia
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
Dosing study of SPC-14 demonstrates efficacy for increasing memory function Englewood Cliffs, NJ – October 20, 2022 – Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage... 
Via FinancialNewsMedia
Silo Pharma Posts Encouraging Preclinical Data For Alzheimer's Candidate
Silo Pharma Inc (NASDAQ: SILO) has announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD). The research was conducted as part of a... 
Via Benzinga
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
Dosing study of SPC-14 demonstrates efficacy for increasing memory function 
From Silo Pharma, Inc.
Via GlobeNewswire
Psychedelics For Alzheimer's And Stress-Induced Disorders Under Study At Columbia University
Silo Pharma Inc. 
Via Benzinga
Florida Dispensary Uncovers Legal Loophole, Starts Selling Shrooms
Via Investor Brand Network
Topics Law Enforcement
Exposures Legal
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement with Columbia University to Extent Research Pact
Via Investor Brand Network
Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics
Silo and Columbia University continue research on SPC-14 for Alzheimer’s and SPC-15 for Stress Induced Disorders 
From Silo Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
Silo Pharma Stock Higher After Investors Appraise Innovative Treatment For Nerve Pain And Neurological Disorders ($SILO)
Via AB Newswire
Exposures Product Safety
Legislators in New York File Revised Measure to Legalize Psychedelics
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Initiates Safety Evaluation Study of Its Novel Time-Released Ketamine Formulation
Via Investor Brand Network
Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma’s Mission To Merge Traditional Pharmaceuticals With Psychedelic Compounds Can Be A Treatment Game-Changer For Neurological Disorders ($SILO)
Via AB Newswire
Exposures Product Safety
Researchers Develop Psychedelic Compound with No Hallucinogenic Effects, Can Treat Depression
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate at Upcoming Dawson James Small Cap Growth Conference
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market
Via Investor Brand Network
How Psychedelic Integration Coaches Help Facilitate Healing
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Preparing for Ketamine Tech FDA Pre-Investigational New Drug Package
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures $5.75M in Underwritten Public Offering
Via Investor Brand Network
Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option
From Silo Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.